Clinical trials: Furmonertinib
Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer
Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)
Global, Phase 3, randomized, multicenter, open-label study evaluating the efficacy and safety of furmonertinib (firmonertinib) at 2 dose levels (160 mg once daily [QD] and 240 mg QD) compared to platinum-based chemotherapy in…
- Conditions
- Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, EGFR Exon 20 Mutations
- Trial name
- NCT05607550
- Testing
- furmonertinib 240 mg oral, daily, furmonertinib 160 mg oral, daily, platinum-based chemotherapy
- Where
- 208 sites in United States, Australia and 17 more
- Volunteers
- 398 people
- Sponsor
- ArriVent BioPharma, Inc.
Non-Small-Cell Lung Cancer
Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC
The aim of this phase Ⅱ study is to evaluate the efficacy and safety of Furmonertinib combined with Anlotinib as the first-line treatment in locally advanced or metastatic non-small cell lung cancer with sensitive EGFR mutations.
- Trial name
- FOCUS-A (NCT04895930)
- Testing
- Furmonertinib, Anlotinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Chest Hospital
Non-Small Cell Lung Cancer
High-dose Furmonertinib or Combined With Chemotherapy in EGFR-mutant Advanced NSCLC After Disease Progression on Third-generation EGFR-TKI
This is a multicenter, open-label,randomised phase II study planned to include 60 subjects with EGFR-sensitive mutation advanced NSCLC after disease progression on first-line treatment with third-generation EGFR-TKI.Eligible…
- Trial name
- NCT06652048
- Testing
- Furmonertinib 160mg QD, Furmonertinib 240mg QD, Furmonertinib 160mg QD plus Chemotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Jialei Wang
Non-small Cell Lung Cancer
Intrathecal Pemetrexed Combined With High-dose Furmonertinib and Beva for EGFR-m NSCLC With Leptomeningeal Metastases
This study aimed to evaluate the efficacy and safety of intrathecal pemetrexed with high-dose Furmonertinib plus bevacizumab for EGFR-mutant non-small cell lung cancer patients with leptomeningeal metastases after resistance to…
- Trial name
- NCT06537297
- Testing
- Intrathecal Pemetrexed and high-dose Furmonertinib plus bevacizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Hunan Province Tumor Hospital
NSCLC
Phase Ib Study of FURMONERTINIB in Patients with NSCLC Having Exon 20 Insertion Mutation
This is a phase 1 multi-center clinical study. To explore the efficacy and safety of Furmonertinib Mesilate at different doses in locally advanced or metastatic NSCLC patients with EGFR exon 20 insertion mutation.
- Trial name
- NCT04958967
- Testing
- Furmonertinib 240mg, Furmonertinib 160mg
- Where
- China
- Sponsor
- Allist Pharmaceuticals, Inc.
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer
Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer （FLAG）
To assess the efficacy and safety of Alflutinib Mesylate versus Gefitinib in patients with locally advanced or Metastatic Non Small Cell Lung Cancer
- Trial name
- NCT03787992
- Testing
- Gefitinib 250 mg
- Where
- China
- Volunteers
- 358 people
- Sponsor
- Allist Pharmaceuticals, Inc.
Lung Cancer, Nonsmall Cell
High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases
The investigators were to explore whether high-dose Furmonertinib, compared with osimertinib, could achieve longer survival in patients with EGFR-mutated NSCLC with CNS metastasis.
- Trial name
- NCT06319950
- Testing
- Furmonertinib, Osimertinib
- Volunteers
- 255 people
- Sponsor
- Taizhou Hospital
Non-small Cell Lung Cancer Metastatic
High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis
the study conducted to evaluate the efficacy and safety of high-dose furmonertinib (160 mg qd) combined with bevacizumab and pemetrexed intrathecal chemotherapy in NSCLC patients with EGFR mutations and meningeal metastases.
- Trial name
- NCT06812871
- Testing
- furmonertinib
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Sun Yat-sen University
NSCLC Stage IV, EGFR Gene Mutation
A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy
Efficacy and Safety of Sacituzumab Tirumotecan Combined with Furmonertinib in Patients with Locally Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy.
- Trial name
- TROP-LUNG (NCT07548060)
- Testing
- sacituzumab tirumotecan
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
NSCLC (Non-small Cell Lung Cancer)
Sacituzumab Tirumotecan in Combination With Furmonertinib as Second-line Treatment for EGFR-mutant Advanced or Metastatic NSCLC After Failure of First-line Third-generation EGFR-TKI Therapy
This study is a multicenter, single-arm, phase II clincial trial. The main objective of the study is to evaluate the efficacy and safety of the combination of Sacituzumab Tirumotecan (sac-TMT) and Furmonertinib in the treatment…
- Trial name
- NCT07193160
- Testing
- Sacituzumab Tirumotecan, Furmonertinib
- Volunteers
- 45 people
- Sponsor
- Fudan University
Non Small Cell Lung Cancer NSCLC
Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure
The goal of phase Ib study was to evaluate efficacy and tolerability of the combination of vebreltinib and furmonertinib in patients with locally advanced or metastatic non-small cell lung cancer with c-met amplification after…
- Trial name
- NCT07087223
- Testing
- Vebreltinib combined with Furmonertinib
- Where
- 12 sites in China
- Volunteers
- 42 people
- Sponsor
- Peking University Cancer Hospital & Institute
Non Small Cell Lung Cancer
Furmonertinib in Patients With Leptomeningeal Metastases Associated With EGFR Mutated NSCLC
The goal of this clinical trial is to evaluate the clinical efficacy and safety of Furmonertinib in EGFR mutated NSCLC patients with leptomeningeal metastasis and to explore the feasibility of CSF ctDNA detection for efficacy…
- Trial name
- NCT05813522
- Testing
- Furmonertinib Mesilate Tablets
- Where
- China
- Volunteers
- 30 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Non Small Cell Lung Cancer, EGFR Gene Mutation
The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC
This study is a single-center, prospective, single-arm study of the efficacy of double-dose Furmonertinib in the treatment of patients with slow Osimertinib-resistant non-small cell lung cancer, mainly in patients with advanced…
- Conditions
- Non Small Cell Lung Cancer, EGFR Gene Mutation, Non Small Cell Lung Cancer Stage IIIA, Non-small Cell Lung Cancer Stage IV
- Trial name
- NCT06117644
- Testing
- Furmonertinib
- Volunteers
- 30 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Lung Cancer (NSCLC), Leptomeningeal Cancer
A Clinical Study of Furmonertinib in the Treatment of EGFR-Mutated NSCLC With Leptomeningeal Metastases
This study adopts a retrospective design. Patients enrolled will include those who received furmonertinib (treatment duration ≥1 month) between March 3, 2021, and December 31, 2024, with concurrent therapies permitted (e.g.…
- Trial name
- NCT06926803
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Qiming Wang
Non-small Cell Lung Cancer
Neoadjuvant Furmonertinib and Cisplatin/Pemetrexed as in EGFR Mutated Stage IIA-IIIB Resectable NSCLC (FORESEE)
In this single-arm, phase II clinical trial, patients with resectable, EGFR-mutated, stage II-IIIB NSCLC received neoadjuvant therapy with furmonertinib (oral, 80 mg once daily, stopped 1 week preoperatively) in combination with…
- Trial name
- NCT05430802
- Testing
- Furmonertinib+cisplating/pemetrexed
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Tang-Du Hospital
Healthy Male Volunteers
Study Evaluating the Mass Balance And Biotransformation of Single Dose[14C] AST2818 in Chinese Healthy Male Volunteers
Study to Evaluate the Mass Balance and Biotransformation of Single Dose[14C] AST2818 in Chinese Healthy Male Volunteers
- Trial name
- NCT03941340
- Testing
- [14]-AST2818
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Allist Pharmaceuticals, Inc.
Non-Small Cell Lung Cancer
A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
Evaluate the efficacy and safety of RC108 in combination with Furmonertinib against Furmonertinib for treatment of EGFR mutation combined with MET-positive unresectable locally advanced or recurrent metastatic NSCLC
- Trial name
- NCT06962865
- Testing
- RC108, Furmonertinib Mesilate Tablets Monotherapy
- Where
- 34 sites in China
- Volunteers
- 80 people
- Sponsor
- RemeGen Co., Ltd.
Non-Small-Cell Lung Cancer
Efficacy and Safety of Furmonertinib in EGFR-Mutant, PD-L1+ Patients With Locally Advanced or Metastatic NSCLC (FUTURE)
The aim of this phase Ⅱ study is to evaluate the efficacy and safety of Furmonertinib in EGFR-Mutant, PD-L1+ Patients With Locally Advanced or Metastatic NSCLC.
- Trial name
- NCT05255406
- Testing
- Furmonertinib (160mg)
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Fudan University